Publications by authors named "P A Newcombe"
Article Synopsis
- The ABLE study aims to assess the quality-of-life outcomes for burn patients by analyzing baseline characteristics of individuals with major burn injuries admitted to a burns center in Queensland, Australia.
- Participants aged 18 and over completed surveys within 28 days post-injury, followed by follow-up interviews at 3, 6, and 12 months, collecting data on demographics, psychosocial aspects, and health-related quality of life.
- Of the 274 participants, predominantly middle-aged males, 71.5% remained in the study after 12 months, revealing important information about the types of burns sustained and the prevalence of prior psychological conditions among participants.
Recent advancement in genome-wide association studies (GWAS) comes from not only increasingly larger sample sizes but also the shift in focus towards underrepresented populations. Multipopulation GWAS increase power to detect novel risk variants and improve fine-mapping resolution by leveraging evidence and differences in linkage disequilibrium (LD) from diverse populations. Here, we expand upon our previous approach for single-population fine-mapping through Joint Analysis of Marginal SNP Effects (JAM) to a multipopulation analysis (mJAM).
View Article and Find Full Text PDFThere remains a paucity of evidence on the early predictors of long-term Health-Related Quality of Life (HRQoL) outcomes post-burn in hospitalised adults. The overall aim of this study was to identify the factors (personal, environmental, burn injury and burn treatment factors) that may predict long-term HRQoL outcomes among adult survivors of hospitalised burn injuries at 12 months post-burn. A total of 274 participants, aged 18 years or over, admitted to a single state-wide burn centre with a burn injury were recruited.
View Article and Find Full Text PDFIntroduction: Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab using longitudinal transcriptomic and proteomic analyses of the 52-week, randomised, phase 3 TULIP-1 and TULIP-2 trials.
Methods: Patients with moderate to severe SLE were enrolled in TULIP-1 and TULIP-2 and received intravenous anifrolumab or placebo alongside standard therapy.